AGENDA
AGENDA
The APP hosts the following on site sessions, that will be also available on “live streaming”. Have a look at the APP Sessions Schedule:
Friday February 21 from 12.30 to 13.30 (CET)
Saturday February 22 from 13.00 to 13.45 (CET)
LIVE STREAMING
SESSION 1
followed by Q&A
Â
Speakers: Jennifer Pollock (UK) – Pierre-Régis Burgel (France)
Summary from EBROW sessions:
- Key messages on Phenotypes and Endotypes of Exacerbations
- Relevant updates on Bronchiectasis and NTM Treatment
LIVE STREAMING SESSION 2 followed by Q&A
Speakers: Mattia Nigro (Italy) – Michal Shteinberg (Israel)
Interesting sum up of the 3 BATTLES presented during EBROW:
- PSEUDOMONAS ERADICATION
- CFTR1 MODULATORS & BRONCHIECTASIS
- ICS2 IN BRONCHIECTASIS
1Cystic Fibrosis Transmembrane Conductance Regulator
2Inhaled Corticosteroids
Saturday February 22 from 16.00 to 18.30 (CET)
Open to the Public Conference “Dialogue on Bronchiectasis”
This session aims to raise awareness of Bronchiectasis plus any associated medical conditions,
and the impact of this disease on patients, families and caregivers
16:00 – 16:10 (CET)
Welcome & introduction
Pierre-RĂ©gis Burgel (France), Francesco Blasi (Italy), James D. Chalmers (UK)
16:10 – 16:30 (CET)
The burden of disease from Bronchiectasis
Alan Timothy (UK)
16:30 – 16:50 (CET)
The European lesson: what is needed for a correct “prise en charge”?
Marlène Murris (France), Stefano Aliberti (Italy)
16:50 – 17:10 (CET)
The needs of patients and caregivers
Justine HamaĂŻde (France) in cooperation with MNT Mon Poumon Mon Air
17:10 – 18:10 (CET)
Round Table
Building a network in bronchiectasis: the rare diseases implication from a French to a European perspective
Introduced by Pierre-RĂ©gis Burgel
Chairs: Pierre-RĂ©gis Burgel (France), Francesco Blasi (Italy) – James D. Chalmers (UK)
Discussants: Bernard Maitre (France), Marlène Murris (France), Thierry Nouvel (CF Europe, France), Jeanette Boyd (ELF, UK)
18:10 – 18:30 (CET)
Conclusion
Pierre-RĂ©gis Burgel (France), Francesco Blasi (Italy), James D. Chalmers (UK)
The Association and Patient Programme has been made possible, thanks to the independent unrestricted support grant from:
